Skip to main navigation Skip to search Skip to main content

Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

  • Noelia Purroy
  • , Yuzhou Evelyn Tong
  • , Camilla K. Lemvigh
  • , Nicoletta Cieri
  • , Shuqiang Li
  • , Erin M. Parry
  • , Wandi Zhang
  • , Laura Z. Rassenti
  • , Thomas J. Kipps
  • , Susan L. Slager
  • , Neil E. Kay
  • , Connie Lesnick
  • , Tait D. Shanafelt
  • , Paolo Ghia
  • , Lydia Scarfò
  • , Kenneth J. Livak
  • , Peter V. Kharchenko
  • , Donna S. Neuberg
  • , Lars Rønn Olsen
  • , Jean Fan
  • Satyen H. Gohil, Catherine J. Wu*
*Corresponding author for this work
  • Broad Institute of Harvard University and Massachusetts Institute of Technology
  • Harvard University
  • Dana-Farber Cancer Institute
  • University of California at San Diego
  • Mayo Clinic Rochester, MN
  • Stanford University
  • Vita-Salute San Raffaele University
  • Johns Hopkins University
  • University College London

Research output: Contribution to journal › Letter › peer-review

Original languageEnglish
JournalBlood
Volume139
Issue number14
Pages (from-to)2252-2256
ISSN0006-4971
DOIs
Publication statusPublished - 2022

Cite this